Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 10/2015

01-10-2015 | Episodic Migraine (R Cowan, Section Editor)

A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine

Authors: Amaal J. Starling, Bert B. Vargas

Published in: Current Pain and Headache Reports | Issue 10/2015

Login to get access

Abstract

Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary.
Literature
1.
Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559–66.CrossRefPubMed
2.
Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.PubMed
3.•
Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–15. This study demonstrated that patients with chronic migraine suffer from a lower healthcare-related quality of life and a higher degree of disability and burden compared to episodic migraine.CrossRefPubMed
4.••
Diener HC, Holle D, Dodick D. Treatment of chronic migraine. Curr Pain Headache Rep. 2011;15(1):64–9. This is an excellent review on the multidisciplinary approach to the treatment of chronic migraine.CrossRefPubMed
5.
Katsarava Z, Buse DC, Manack AN, et al. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86–92.PubMedCentralCrossRefPubMed
6.
The International Classification of Headache Disorders, 3rd edition (beta version). 2013; 33 (9): 629-808
7.
Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache. 2011;51 Suppl 2:77–83.CrossRefPubMed
8.•
Starling AJ, Dodick DW. Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. Mayo Clin Proc. 2015;90(3):408–14. This review defines the role of a primary care physician (PCP) in the treatment of chronic migraine.The PCP plays a critical role in the identification of chronic migraine patients, timely referral to a headache specialist, and treatment of comorbidities and risk factors associated with chronic migraine.CrossRefPubMed
9.••
Lipton RB, Serrano D, Buse DC, et al. Improving the detection of chronic migraine: development and validation of identify chronic migraine (ID-CM). Cephalalgia: an international journal of headache 2015. This study validated an easy-to-use case finding tool for the identification of patients with chronic migraine. It can be used by general neurologists and non-neurologists
10.
11.
Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–23.CrossRefPubMed
12.
Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–80.CrossRefPubMed
13.
Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23(8):820–4.CrossRefPubMed
14.
Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.CrossRefPubMed
15.
Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.CrossRefPubMed
16.••
Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36. This pooled analysis demonstrated that onabotulinumtoxinA injections per the PREEMPT protocol are effective for the prevention of chronic migraine with or without medication overuse.CrossRefPubMed
17.
Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358–73.CrossRefPubMed
18.
Yurekli VA, Akhan G, Kutluhan S, et al. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9(1):37–41.PubMedCentralCrossRefPubMed
19.
Saper JR, Lake 3rd AE, Cantrell DT, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42(6):470–82.CrossRefPubMed
20.
Spira PJ, Beran RG. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61(12):1753–9.CrossRefPubMed
21.
Magalhaes E, Menezes C, Cardeal M, et al. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112(6):463–6.CrossRefPubMed
22.
Bigal M, Rapoport A, Sheftell F, et al. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9):1337–42.CrossRefPubMed
23.
Pascual-Gomez J, Alana-Garcia M, Oterino A, et al. Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate. Rev Neurol. 2008;47(9):449–51.PubMed
24.
25.
Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, et al. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010;33(1):35–9.CrossRefPubMed
26.
Weibelt S, Andress-Rothrock D, King W, et al. Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcome. Headache. 2010;50(6):1041–4.CrossRefPubMed
27.
Kaniecki RG. Management of chronic migraine with quarterly pericranial nerve blocks: a prospective 12-month trial. Headache 2012; 52:908: P85.
28.
Inan LE, Inan N, Karadas O, et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand 2015.
29.
Cady R, Saper J, Dexter K, et al. A double-blind, placebo-controlled study of repetitive transnasal sphenopalatine ganglion blockade with tx360((R)) as acute treatment for chronic migraine. Headache. 2015;55(1):101–16.PubMedCentralCrossRefPubMed
30.
Cady RK, Saper J, Dexter K, et al. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. Headache. 2015;55(4):529–42.CrossRefPubMed
31.
Saper JR, Dodick DW, Silberstein SD, et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011;31(3):271–85.PubMedCentralCrossRefPubMed
32.
Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012;32(16):1165–79.CrossRefPubMed
33.
Lipton RB, Goadsby PJ, Cady RK, et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine [abstract P047]. Cephalalgia. 2009;29:30.
34.
Hann S, Sharan A. Dual occipital and supraorbital nerve stimulation for chronic migraine: a single-center experience, review of literature, and surgical considerations. Neurosurg Focus. 2013;35(3):E9.CrossRefPubMed
35.
Reed KL, Black SB, Banta 2nd CJ, et al. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia. 2010;30(3):260–71.PubMed
36.
Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821–8.CrossRefPubMed
37.
Griffiths RR, Evans SM, Heishman SJ, et al. Low-dose caffeine physical dependence in humans. J Pharmacol Exp Ther. 1990;255(3):1123–32.PubMed
38.•
Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–88. This is the first study evaluating oral medication adherence in chronic migraine patients. It demonstrated the adherence is poor at 6 months and even lower at 12 months.CrossRefPubMed
39.
Dodick D. Finding a fit: strategies for chronic migraine prophylaxis. Johns Hopkins Adv Stud Med 2006; 6(4D)
40.
Chen YC, Tang CH, Ng K, et al. Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan. J Headache Pain. 2012;13(4):311–9.PubMedCentralCrossRefPubMed
41.
Teixeira AL, Costa EA, Da Silva Jr AA, et al. Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples. J Headache Pain. 2012;13(7):551–5.PubMedCentralCrossRefPubMed
42.
Verrotti A, Agostinelli S, D'Egidio C, et al. Impact of a weight loss program on migraine in obese adolescents. Eur J Neurol. 2013;20(2):394–7.CrossRefPubMed
43.
Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the nonpharmacologic management of migraine in clinical practice. Can Headache Soc Cmaj. 1998;159(1):47–54.
44.
Varkey E, Cider A, Carlsson J, et al. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011;31(14):1428–38.PubMedCentralCrossRefPubMed
Metadata
Title
A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine
Authors
Amaal J. Starling
Bert B. Vargas
Publication date
01-10-2015
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 10/2015
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-015-0521-0